Collaboration combines Novo Nordisk’ s scientific leadership in obesity and cardiometabolic diseases with Septerna’ s expertise in G protein-coupled receptor drug discovery Goal is to develop ...

The latest announcement is out from Septerna, Inc. ( (SEPN) ).

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments.

Novo Nordisk and Septerna will jointly initiate four preclinical development programmes, targeting well-established metabolic receptors for glucagon-like peptide 1 (GLP-1), gastric inhibitory ...

May 16 (UPI) -- Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Novo Nordisk on Wednesday said it will collaborate with biotechnology startup Septerna to hunt new obesity drug prospects, agreeing to pay the California drugmaker more than $200 million in ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop ...